Aptamers: Design, Theory, and Applications to Diagnosis and Therapy for Diseases

Abstract

Single-stranded DNA or RNA entities referred to as aptamers exhibit a strong affinity and specificity for attaching to specific targets. Owing to their special properties, which include simplicity of synthesis, low immunogenicity, and adaptability in targeting a variety of substances, these synthetic oligonucleotides have garnered a lot of interest. The function of aptamers can be altered by combining them with complementary oligonucleotides “antidotes,” which are antisense to a particular aptamer sequence. Antidotes play an important role in several fields by specifically targeting the corresponding section of the aptamer. Nevertheless, even with their promising capabilities, the creation of antidotes to regulate or inhibit aptamer function continues to be a relatively unexamined field, constraining their secure and efficient application in medical environments. The review explores experimental methodologies for creating antidotes, the systematic design strategies for managing antidotes in aptamer-based therapies, and their therapeutic efficacy in counteracting disease biomarkers. Additionally, it highlights their diagnostic applications in biosensing and imaging, offering a promising alternative to traditional antibodies. It also investigates the progress, latest innovations, and potential medical uses of aptamer–antidote combinations. Its academic value lies in bridging the gap between theoretical design and practical applications, providing researchers and clinicians with a comprehensive resource to advance aptamer-based solutions in medicine and biotechnology.

Keywords

antidote / aptamer / reversible therapeutics

References

[1] H. Guo, X. Xu, J. Zhang, et al., “The Pivotal Role of Preclinical Animal Models in Anti-Cancer Drug Discovery and Personalized Cancer Therapy Strategies,” Pharmaceuticals 17, no. 8 (2024): 1048.

[2] H. Tani, “Recent Advances and Prospects in RNA Drug Development,” International Journal of Molecular Sciences 25, no. 22 (2024): 12284.

[3] J. Xie, Y. Wang, W. Choi, et al., “Overcoming Barriers in Photodynamic Therapy Harnessing Nano-formulation Strategies,” Chemical Society Reviews 50, no. 16 (2021): 9152-9201.

[4] R. Didarian, H. K. Ozbek, V. C. Ozalp, O. Erel, and N. Yildirim-Tirgil, “Enhanced SELEX Platforms for Aptamer Selection With Improved Characteristics: A Review,” Molecular Biotechnology (2024): 1-16.

[5] N. Jain, A. Singh, and D. Bhatia, “DNA-amphiphilic Nanostructures: Synthesis, Characterization and Applications,” Nanoscale 17 (2025): 18-52.

[6] L. Wu, Y. Wang, X. Xu, et al., “Aptamer-based Detection of Circulating Targets for Precision Medicine,” Chemical Reviews 121, no. 19 (2021): 12035-12105.

[7] S. Malhotra, S. Singh, R. Mala, and S. Sood, “Aptamer Selection: Choosing the Appropriate SELEX,” Indian J Pure Appl Biosci 9, no. 2 (2021): 240-253.

[8] D. Sanjanwala and V. Patravale, “Aptamers and Nanobodies as Alternatives to Antibodies for Ligand-targeted Drug Delivery in Cancer,” Drug Discovery Today 28, no. 5 (2023): 103550.

[9] M. Domsicova, J. Korcekova, A. Poturnayova, and A. Breier, “New Insights Into Aptamers: An Alternative to Antibodies in the Detection of Molecular Biomarkers,” International Journal of Molecular Sciences 25, no. 13 (2024): 6833.

[10] A. Ahmad, M. Imran, and H. Ahsan, “Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases,” Pharmaceutics 15, no. 6 (2023): 1630.

[11] Y. Zhang, H. Zhang, D. W. H. Chan, et al., “Strategies for Developing Long-lasting Therapeutic Nucleic Acid Aptamer Targeting Circulating Protein: The Present and the Future,” Frontiers in Cell and Developmental Biology 10 (2022): 1048148.

[12] M. Stephens, “The Emerging Potential of Aptamers as Therapeutic Agents in Infection and Inflammation,” Pharmacology & Therapeutics 238 (2022): 108173.

[13] L. Li, S. Xu, H. Yan, et al., “Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives,” Angewandte Chemie International Edition 60, no. 5 (2021): 2221-2231.

[14] A. Krissanaprasit, C. M. Key, S. Pontula, and T. H. LaBean, “Self-assembling Nucleic Acid Nanostructures Functionalized With Aptamers,” Chemical Reviews 121, no. 22 (2021): 13797-13868.

[15] W. Szymanowski, A. Szymanowska, A. Bielawska, G. Lopez-Berestein, C. Rodriguez-Aguayo, and P. Amero, “Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges,” Cancers 15, no. 21 (2023): 5300.

[16] S. Jain, J. Kaur, S. Prasad, and I. Roy, “Nucleic Acid Therapeutics: A Focus on the Development of Aptamers,” Expert Opinion on Drug Discovery 16, no. 3 (2021): 255-274.

[17] B. Wang, A. H. Wan, Y. Xu, et al., “Identification of Indocyanine Green as a STT3B Inhibitor Against Mushroom α-amanitin Cytotoxicity,” Nature Communications 14, no. 1 (2023): 2241.

[18] R. Chowdhury, S. Eslami, C. V. Pham, et al., “Role of Aptamer Technology in Extracellular Vesicle Biology and Therapeutic Applications,” Nanoscale 16, no. 24 (2024): 11457-11479.

[19] F. Mohammadi, H. Zahraee, F. Zibadi, et al., “Progressive Cancer Targeting by Programmable Aptamer-tethered Nanostructures,” MedComm 5, no. 11 (2024): e775.

[20] S. Sujith, R. Naresh, B. Srivisanth, et al., “Aptamers: Precision Tools for Diagnosing and Treating Infectious Diseases,” Frontiers in Cellular and Infection Microbiology 14 (2024): 1402932.

[21] W.-R. Cui, Y.-R. Chen, W. Xu, et al., “A Three-dimensional Luminescent Covalent Organic Framework for Rapid, Selective, and Reversible Uranium Detection and Extraction,” Separation and Purification Technology 306 (2023): 122726.

[22] J. Chen, Q. Peng, X. Peng, H. Zhang, and H. Zeng, “Probing and Manipulating Noncovalent Interactions in Functional Polymeric Systems,” Chemical Reviews 122, no. 18 (2022): 14594-14678.

[23] R. L. Shoemaker, R. J. Larsen, and P. A. Larsen, “Single-domain Antibodies and Aptamers Drive New Opportunities for Neurodegenerative Disease Research,” Frontiers in Immunology 15 (2024): 1426656.

[24] A. Sheikh, S. Md, N. A. Alhakamy, and P. Kesharwani, “Recent Development of aptamer Conjugated Chitosan Nanoparticles as Cancer Therapeutics,” International Journal of Pharmaceutics 620 (2022): 121751.

[25] C. Ji, J. Wei, L. Zhang, et al., “Aptamer-protein Interactions: From Regulation to Biomolecular Detection,” Chemical Reviews 123, no. 22 (2023): 12471-12506.

[26] A. A. Mohammed, D. AlShaer, and O. Al Musaimi, “Oligonucleotides: Evolution and Innovation,” Medicinal Chemistry Research (2024): 1-17.

[27] T. S. Yeoh, T. H. Tang, and M. Citartan, “Isolation of a Novel DNA Aptamer Against LipL32 as a Potential Diagnostic Agent for the Detection of Pathogenic Leptospira.” Biotechnology Journal 18, no. 3 (2023): e2200418.

[28] M. C. DeRosa, A. Lin, P. Mallikaratchy, et al., “In Vitro Selection of Aptamers and Their Applications,” Nature Reviews Methods Primers 3, no. 1 (2023): 54.

[29] V. Léguillier, B. Heddi, and J. Vidic, “Recent Advances in Aptamer-based Biosensors for Bacterial Detection,” Biosensors 14, no. 5 (2024): 210.

[30] M. Janghorban, S. Kazemi, R. Tormon, P. Ngaju, and R. Pandey, “Methods and Analysis of Biological Contaminants in the Biomanufacturing Industry,” Chemosensors 11, no. 5 (2023): 298.

[31] R. Cai, X. Chen, Y. Zhang, X. Wang, and N. Zhou, “Systematic Bio-fabrication of Aptamers and Their Applications in Engineering Biology,” Systems Microbiology and Biomanufacturing 3, no. 2 (2023): 223-245.

[32] J. Zhou; and J. Rossi, “Aptamers as Targeted Therapeutics: Current Potential and Challenges,” Nature Reviews Drug Discovery, 16, no. 3 (2017): 181-202.

[33] R. Stoltenburg, C. Reinemann, and B. Strehlitz, “SELEX-a (r)Evolutionary Method to Generate High-affinity Nucleic Acid Ligands,” Biomolecular Engineering 24, no. 4 (2007): 381-403.

[34] F. Curti, S. Fortunati, W. Knoll, M. Giannetto, R. Corradini, A. Bertucci, and M. Careri, “A Folding-Based Electrochemical Aptasensor for the Single-Step Detection of the SARS-CoV-2 Spike Protein,” ACS Applied Materials & Interfaces 14, no. 17 (2022): 19204-19211.

[35] D. Wu, C. K. Gordon, J. H. Shin, M. Eisenstein, and H. T. Soh, “Directed Evolution of aptamer Discovery Technologies,” Accounts of Chemical Research 55, no. 5 (2022): 685-695.

[36] J. Kim, J. F. Quijano, J. Kim, E. Yeung, and R. M. Murray, “Synthetic Logic Circuits Using RNA Aptamer Against T7 RNA Polymerase,” Biotechnology Journal 17, no. 3 (2022): 2000449.

[37] M. Kohlberger and G. Gadermaier, “SELEX: Critical Factors and Optimization Strategies for Successful Aptamer Selection,” Biotechnology and Applied Biochemistry, 69, no. 5 (2022): 1771-1792.

[38] C. Chandola, S. Kalme, M. G. Casteleijn, A. Urtti, and M. Neerathilingam, “Application of Aptamers in Diagnostics, Drug-delivery and Imaging,” Journal of Biosciences 41 (2016): 535-561.

[39] Z. Fan, Y. Liu, Y. Ye, and Y. Liao, “Functional Probes for the Diagnosis and Treatment of Infectious Diseases,” Aggregate 5, no. 6 (2024): e620.

[40] J. Kirsch, C. Siltanen, Q. Zhou, A. Revzin, and A. Simonian, “Biosensor Technology: Recent Advances in Threat Agent Detection and Medicine,” Chemical Society Reviews 42, no. 22 (2013): 8733-8768.

[41] S. Vigneshvar, C. Sudhakumari, B. Senthilkumaran, and H. Prakash, “Recent Advances in Biosensor Technology for Potential Applications-an Overview,” Frontiers in Bioengineering and Biotechnology 4 (2016): 11.

[42] J. Cao, Y. Yao, K. Fan, et al., “Harnessing a Previously Unidentified Capability of Bacterial Allosteric Transcription Factors for Sensing Diverse Small Molecules in Vitro,” Science Advances no. 11 (2018): eaau4602.

[43] S. Ma, Q. Ren, L. Jiang, et al., “A Triple-aptamer Tetrahedral DNA Nanostructures Based Carbon-nanotube-array Transistor Biosensor for Rapid Virus Detection,” Talanta 266 (2024): 124973.

[44] Y. Liu, A. George, M. Shojaee, et al., “A Wireless Electrochemical Aptamer-Based Biosensor Platform Utilizing Printed Circuit Board Electrodes for Drug Monitoring Applications,” Microchemical Journal 204 (2024): 111038.

[45] Y. Zhang, K. Bi, L. Zhou, et al., “Advances in Blood Biomarkers for Alzheimer's Disease: Ultra-Sensitive Detection Technologies and Impact on Clinical Diagnosis,” Degenerative Neurological and Neuromuscular Disease 14 (2024): 85-102.

[46] O. G. Chavez-Pineda, R. Rodriguez-Moncayo, D. F. Cedillo-Alcantar, P. E. Guevara-Pantoja, J. U. Amador-Hernandez, and J. L. Garcia-Cordero, “Microfluidic Systems for the Analysis of Blood-derived Molecular Biomarkers,” Electrophoresis 43, no. 16-17 (2022): 1667-1700.

[47] X. Hu, D. Zhang, Z. Zeng, L. Huang, X. Lin, and S. Hong, “Aptamer-based Probes for Cancer Diagnostics and Treatment,” Life 12, no. 11 (2022): 1937.

[48] T. A. Bodily, A. Ramanathan, S. Wei, et al., “In Pursuit of Degenerative Brain Disease Diagnosis: Dementia Biomarkers Detected by DNA Aptamer-attached Portable Graphene Biosensor,” Proceedings of the National Academy of Sciences 120, no. 47 (2023): e2311565120.

[49] A. Arroyo, B. Kim, and J. Yeh, “Luteinizing Hormone Action in human Oocyte Maturation and Quality: Signaling Pathways, Regulation, and Clinical Impact,” Reproductive Sciences 27, no. 6 (2020): 1223-1252.

[50] Y. Ming, Y. Liu, D. Li, B. Jiang, Y. Xiang, and R. Yuan, “Low Background Catalytic Redox Recycling Coupled With Hybridization Chain Reaction Amplification for Highly Sensitive Electrochemical Aptamer Luteinizing Hormone Assay,” Bioelectrochemistry (2024): 108888.

[51] D. Pan, Y. Lin, X. Liu, Y. Xin, Q. Tian, and J. Zhang, “Ultrasensitive and Preprocessing-free Electrochemical Biosensing Platform for the Detection of Cancer-derived Exosomes Based on Spiky-shaped Aptamer-magnetic Beads,” Biosensors & Bioelectronics 217 (2022): 114705, https://doi.org/10.1016/j.bios.2022.114705. From NLM.

[52] S. Gao, Q. Li, S. Zhang, et al., “A Novel Biosensing Platform for Detection of Glaucoma Biomarker GDF15 via an Integrated BLI-ELASA Strategy,” Biomaterials 294 (2023): 121997.

[53] S. Kumar, A. Mohan, N. R. Sharma, et al., “Computational Frontiers in Aptamer-based Nanomedicine for Precision Therapeutics: A Comprehensive Review,” ACS Omega 9, no. 25 (2024): 26838-26862.

[54] Y. Tang, L. Yao, Y. Wang, et al., “Signal-on Lateral Flow Immunoassays for Rapid Detection of Tetrodotoxin in Pufferfish,” Journal of Hazardous Materials 486 (2025): 136973.

[55] B. Wang, F. Kobeissy, M. Golpich, et al., “Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development,” Molecules (Basel, Switzerland) 29, no. 5 (2024): 1124.

[56] J. C. Laguna, M. García-Pardo, J. Alessi, et al., “Geographic Differences in Lung Cancer: Focus on Carcinogens, Genetic Predisposition, and Molecular Epidemiology,” Therapeutic Advances in Medical Oncology 16 (2024): 17588359241231260.

[57] J. Zhou, Y. Xu, J. Liu, L. Feng, J. Yu, and D. Chen, “Global Burden of Lung Cancer in 2022 and Projections to 2050: Incidence and Mortality Estimates From GLOBOCAN,” Cancer Epidemiology 93 (2024): 102693.

[58] A. M. K. Sherani, M. Khan, M. U. Qayyum, and H. K. Hussain, “Synergizing AI and Healthcare: Pioneering Advances in Cancer Medicine for Personalized Treatment,” International Journal of Multidisciplinary Sciences and Arts 3, no. 2 (2024): 270-277.

[59] L. Li, J. Wan, X. Wen, et al., “Identification of a New DNA Aptamer by Tissue-SELEX for Cancer Recognition and Imaging,” Analytical Chemistry 93, no. 19 (2021): 7369-7377.

[60] R. A. Herman, E. Ayepa, W.-X. Zhang, et al., “Molecular Modification and Biotechnological Applications of Microbial Aspartic Proteases,” Critical Reviews in Biotechnology 44, no. 3 (2024): 388-413.

[61] Z. Xiang, J. Zhao, D. Yi, Z. Di, and L. Li, “Peptide Nucleic Acid (PNA)-guided Peptide Engineering of an aptamer Sensor for Protease-triggered Molecular Imaging,” Angewandte Chemie 133, no. 42 (2021): 22841-22845.

[62] M. Plebani, J. H. Nichols, P. B. Luppa, et al., “Point-of-care Testing: State-of-the Art and Perspectives,” Clinical Chemistry and Laboratory Medicine (CCLM) 63, no. 1 (2025): 35-51.

[63] S. Chakraborty, “Democratizing Nucleic Acid-based Molecular Diagnostic Tests for Infectious Diseases at Resource-limited Settings-From Point of Care to Extreme Point of Care,” Sensors & Diagnostics 3, no. 4 (2024): 536-561.

[64] B. Ofori, S. Twum, S. N. Yeboah, F. Ansah, and K. A. N. Sarpong, “Towards the Development of Cost-effective Point-of-care Diagnostic Tools for Poverty-related Infectious Diseases in sub-Saharan Africa,” PeerJ 12 (2024): e17198.

[65] E. I. Obeagu and G. U. Obeagu, “Strengthening Laboratory Systems for Ensuring Accurate Diagnoses in Mother-to-child Transmission (MTCT) Prevention Programs in Uganda: A Narrative Review,” Annals of Medicine and Surgery 86, no. 9 (2024): 5256-5265.

[66] C. A. Alvarez-Moreno, E. S. A. de Araújo, E. Baumeister, et al., “Differential Diagnosis in the Management of Acute Respiratory Infections Through Point-of-Care Rapid Testing in a Post-Pandemic Scenario in Latin America: Special Focus on COVID-19, Influenza, and Respiratory Syncytial Virus,” COVID 4, no. 2 (2024): 221-260.

[67] M. Citartan and T.-H. Tang, “Recent Developments of Aptasensors Expedient for Point-of-care (POC) Diagnostics,” Talanta 199 (2019): 556-566.

[68] A. Futane, V. Narayanamurthy, P. Jadhav, and A. Srinivasan, “Aptamer-based Rapid Diagnosis for Point-of-care Application,” Microfluidics and Nanofluidics 27, no. 2 (2023): 15.

[69] S. Adiningsih, M. Widiyanti, A. Hermawan, H. H. Idrus, and R. Fitrianingtyas, “Low Cluster of Differentiation 4+ T-cell Count Associated With Thrombocytopenia Among People Living With human Immunodeficiency Virus-1 Receiving Antiretroviral in West Papua,” Journal of Medical Microbiology 74, no. 1 (2025): 001958.

[70] A. S. Rizvi, G. Murtaza, W. Zhang, M. Xue, L. Qiu, and Z. Meng, “Aptamer-linked Photonic Crystal Hydrogel Sensor for Rapid Point-of-care Detection of human Immuno-deficiency Virus-1 (HIV-1),” Journal of Pharmaceutical and Biomedical Analysis 227 (2023): 115104.

[71] R. M. Dirkzwager, S. Liang, and J. A. Tanner, “Development of aptamer-based Point-of-care Diagnostic Devices for Malaria Using Three-dimensional Printing Rapid Prototyping,” Acs Sensors 1, no. 4 (2016): 420-426.

[72] J. Wang, Q. Wang, Y. Zhong, D. Wu, and N. Gan, “A Sandwich-type Aptasensor for Point-of-care Measurements of Low-density Lipoprotein in Plasma Based on aptamer-modified MOF and Magnetic Silica Composite Probes,” Microchemical Journal 158 (2020): 105288.

[73] S. Wittlin and P. Mäser, “From Magic Bullet to Magic Bomb: Reductive Bioactivation of Antiparasitic Agents,” ACS Infectious Diseases 7, no. 10 (2021): 2777-2786.

[74] T. C. Ezike, U. S. Okpala, U. L. Onoja, et al., “Advances in Drug Delivery Systems, Challenges and Future Directions,” Heliyon 9, no. 6 (2023): e17488.

[75] D. Park, S. J. Lee, and J.-W. Park, “Aptamer-Based Smart Targeting and Spatial Trigger-Response Drug-Delivery Systems for Anticancer Therapy,” Biomedicines 12, no. 1 (2024): 187.

[76] M. Chehelgerdi, M. Chehelgerdi, O. Q. B. Allela, et al., “Progressing Nanotechnology to Improve Targeted Cancer Treatment: Overcoming Hurdles in Its Clinical Implementation,” Molecular Cancer 22, no. 1 (2023): 169.

[77] F. Riccardi, M. Dal Bo, P. Macor, and G. Toffoli, “A Comprehensive Overview on Antibody-drug Conjugates: From the Conceptualization to Cancer Therapy,” Frontiers in Pharmacology 14 (2023): 1274088.

[78] J. S. Trivedi, M. Yasir, R. K. Maurya, and A. S. Tripathi, “Aptamer-based Theranostics in Oncology: Design Strategies and Limitations,” BIO Integration no. 1 (2024): 993.

[79] J. Zhao, P. Liu, J. Ma, et al., “Enhancement of Radiosensitization by Silver Nanoparticles Functionalized With Polyethylene Glycol and Aptamer As1411 for Glioma Irradiation Therapy,” International Journal of Nanomedicine 14 (2019): 9483-9496.

[80] Y. Yang, W. Zhao, W. Tan, et al., “An Efficient Cell-targeting Drug Delivery System Based on Aptamer-modified Mesoporous Silica Nanoparticles,” Nanoscale Research Letters 14 (2019): 1-10.

[81] M. Mohammadi, Z. Salmasi, M. Hashemi, F. Mosaffa, K. Abnous, and M. Ramezani, “Single-walled Carbon Nanotubes Functionalized With Aptamer and Piperazine-polyethylenimine Derivative for Targeted siRNA Delivery Into Breast Cancer Cells,” International Journal of Pharmaceutics 485, no. 1-2 (2015): 50-60.

[82] F. Li, J. Lu, J. Liu, et al., “A Water-soluble Nucleolin Aptamer-paclitaxel Conjugate for Tumor-specific Targeting in Ovarian Cancer,” Nature Communications 8, no. 1 (2017): 1390.

[83] M. Akbarzadeh, M. Babaei, K. Abnous, et al., “Hybrid Silica-coated Gd-Zn-Cu-In-S/ZnS Bimodal Quantum Dots as an Epithelial Cell Adhesion Molecule Targeted Drug Delivery and Imaging System,” International Journal of Pharmaceutics 570 (2019): 118645.

[84] X. Li, X. Wu, H. Yang, L. Li, Z. Ye, and Y. Rao, “A Nuclear Targeted Dox-aptamer Loaded Liposome Delivery Platform for the Circumvention of Drug Resistance in Breast Cancer,” Biomedicine & Pharmacotherapy 117 (2019): 109072.

[85] R. Urmi, P. Banerjee, M. Singh, et al., “Revolutionizing Biomedicine: Aptamer-based Nanomaterials and Nanodevices for Therapeutic Applications,” Biotechnology Reports 42 (2024): e00843.

[86] K. Ghasemii, M. Darroudi, I. Rahimmanesh, et al., “Advances in aptamer-based Drug Delivery Vehicles for Cancer Therapy,” Biomaterials Advances 140 (2022): 213077.

[87] W. Zhang, R. Taheri-Ledari, F. Ganjali, et al., “Nanoscale Bioconjugates: A Review of the Structural Attributes of Drug-loaded Nanocarrier Conjugates for Selective Cancer Therapy,” Heliyon 8, no. 6 (2022): e09577.

[88] N. Bidar, F. Oroojalian, B. Baradaran, et al., “Monitoring of microRNA Using Molecular Beacons Approaches: Recent Advances,” TrAC Trends in Analytical Chemistry 131 (2020): 116021.

[89] J. Georgeous, N. AlSawaftah, W. H. Abuwatfa, and G. A. Husseini, “Review of Gold Nanoparticles: Synthesis, Properties, Shapes, Cellular Uptake, Targeting, Release Mechanisms and Applications in Drug Delivery and Therapy,” Pharmaceutics 16, no. 10 (2024): 1332.

[90] M. Alikhani, M. Ramezani, K. Abnous, S. M. Taghdisi, S. Nekooei, and M. Alibolandi, “Synthesis of Theranostic aptamer Targeted Polydopamine-coated Gold Nanocages for Chemo-photothermal Therapy Against Melanoma,” Journal of Drug Delivery Science and Technology 103 (2025): 106443.

[91] R. Yazdian-Robati, P. Bayat, S. Dehestani, M. Hashemi, S. M. Taghdisi, and K. Abnous, “Smart Delivery of Epirubicin to Cancer Cells Using aptamer-modified Ferritin Nanoparticles,” Journal of Drug Targeting 30, no. 5 (2022): 567-576.

[92] A. Abrishami, A. R. Bahrami, A. S. Saljooghi, and M. M. Matin, “Enhanced Theranostic Efficacy of Epirubicin-loaded SPION@ MSN Through co-delivery of an Anti-miR-21-expressing Plasmid and ZIF-8 Hybridization to Target Colon Adenocarcinoma,” Nanoscale 16, no. 12 (2024): 6215-6240.

[93] P. Krzyszczyk, A. Acevedo, E. J. Davidoff, et al., “The Growing Role of Precision and Personalized Medicine for Cancer Treatment,” Technology 6 (2018): 03n04.

[94] D.-R. Wang, X.-L. Wu, and Y.-L. Sun, “Therapeutic Targets and Biomarkers of Tumor Immunotherapy: Response versus Non-response,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 331.

[95] C. Peterson, N. Denlinger, and Y. Yang, “Recent Advances and Challenges in Cancer Immunotherapy,” Cancers 14, no. 16 (2022): 3972.

[96] N. E. Welty and S. I. Gill, “Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review,” Cardio Oncology 4, no. 5 (2022): 563-578.

[97] F. Pastor, D. Kolonias, P. H. Giangrande, and E. Gilboa, “Induction of Tumour Immunity by Targeted Inhibition of Nonsense-mediated mRNA Decay,” Nature 465, no. 7295 (2010): 227-230.

[98] H. Huang, J. Fu, H. Peng, et al., “Co-delivery of Polyphyllin II and IR780 PLGA Nanoparticles Induced Pyroptosis Combined With Photothermal to Enhance Hepatocellular Carcinoma Immunotherapy,” Journal of Nanobiotechnology 22, no. 1 (2024): 647, https://doi.org/10.1186/s12951-024-02887-6.

[99] J. Xu, Y. Zhang, Y. Zheng, et al., “A Smart Responsive NIR-operated Chitosan-based Nanoswitch to Induce Cascade Immunogenic Tumor Ferroptosis via Cytokine Storm,” Carbohydrate Polymers 351 (2025): 123120.

[100] J.-H. Wang, D. J. Gessler, W. Zhan, T. L. Gallagher, and G. Gao, “Adeno-associated Virus as a Delivery Vector for Gene Therapy of human Diseases,” Signal Transduction and Targeted Therapy 9, no. 1 (2024): 78.

[101] R. Luo, H. Le, Q. Wu, and C. Gong, “Nanoplatform-based in Vivo Gene Delivery Systems for Cancer Therapy,” Small 20, no. 30 (2024): 2312153.

[102] T. Sato, S. Chaugule, M. B. Greenblatt, G. Gao, and J.-H. Shim, “Advances in Bone-targeting Drug Delivery: Emerging Strategies Using Adeno-associated Virus,” Human Gene Therapy 35, no. 9-10 (2024): 329-341.

[103] S. Zheng, M. Luo, H. Huang, et al., “New Insights Into the Role of Mitophagy Related Gene Affecting the Metastasis of Osteosarcoma Through scRNA-seq and CRISPR-Cas9 Genome Editing,” Cell Communication and Signaling: CCS 22 (2024): 592.

[104] I. Larionova, E. Kazakova, T. Gerashchenko, and J. Kzhyshkowska, “New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis,” Cancers 13, no. 13 (2021): 3253.

[105] S. Du, Z. Yang, X. Lu, et al., “Anoikis Resistant Gastric Cancer Cells Promote Angiogenesis and Peritoneal Metastasis Through C/EBPβ-mediated PDGFB Autocrine and Paracrine Signaling,” Oncogene 40, no. 38 (2021): 5764-5779.

[106] Z.-D. Shi, K. Pang, Z.-X. Wu, et al., “Tumor Cell Plasticity in Targeted Therapy-induced Resistance: Mechanisms and New Strategies,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 113.

[107] C. Liang, F. Li, L. Wang, et al., “Tumor Cell-targeted Delivery of CRISPR/Cas9 by aptamer-functionalized Lipopolymer for Therapeutic Genome Editing of VEGFA in Osteosarcoma,” Biomaterials 147 (2017): 68-85, https://doi.org/10.1016/j.biomaterials.2017.09.015. From NLM.

[108] Z. Khademi, M. Ramezani, M. Alibolandi, et al., “A Novel Dual-targeting Delivery System for Specific Delivery of CRISPR/Cas9 Using Hyaluronic Acid, Chitosan and AS1411,” Carbohydrate Polymers 292 (2022): 119691, https://doi.org/10.1016/j.carbpol.2022.119691. From NLM.

[109] S. Sarkar, P. Moitra, W. Duan, and S. Bhattacharya, “A Multifunctional Aptamer Decorated Lipid Nanoparticles for the Delivery of EpCAM-Targeted CRISPR/Cas9 Plasmid for Efficacious in Vivo Tumor Regression,” Advanced Healthcare Materials 13, no. 31 (2024): 2402259.

[110] A. H.-Y. Kong, A. J. Wu, O. K.-Y. Ho, et al., “Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges,” International Journal of Molecular Sciences 24, no. 14 (2023): 11780.

[111] O. Alkhamis and Y. Xiao, “Systematic Study of in Vitro Selection Stringency Reveals How to Enrich High-affinity Aptamers,” Journal of the American Chemical Society 145, no. 1 (2022): 194-206.

[112] D. Ostroverkhova, K. Tyryshkin, A. K. Beach, et al., “DNA Polymerase ε and δ Variants Drive Mutagenesis in Polypurine Tracts in human Tumors,” Cell Reports 43, no. 1 (2024): 113655.

[113] A. K. Singh and R. Malviya, “Coagulation and Inflammation in Cancer: Limitations and Prospects for Treatment,” Biochimica Et Biophysica Acta (BBA)-Reviews on Cancer 1877, no. 3 (2022): 188727.

[114] D. P. Rath and A. P. Singh, “Comprehensive Perspective on Coronary Heart Disease: A Review,” Research & Reviews: A Journal of Neuroscience 14, no. 1 (2024): 26-40p. Comprehensive Perspective on Coronary Heart Disease Rath and Singh STM Journals 2024, 2.

[115] D. Werring, M. Adams, L. Benjamin, et al., “Stroke and Cerebrovascular Diseases,” Neurology: A Queen Square Textbook (2024): 107-198.

[116] C. Hsu, E. Hutt, D. M. Bloomfield, D. Gailani, and J. I. Weitz, “Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week,” Journal of the American College of Cardiology 78, no. 6 (2021): 625-631.

[117] E. L. Howard, K. C. Becker, C. P. Rusconi, and R. C. Becker, “Factor IXa Inhibitors as Novel Anticoagulants,” Arteriosclerosis, Thrombosis, and Vascular Biology 27, no. 4 (2007): 722-727.

[118] E. KA, “ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery),” Circulation 100 (1999): 1464-1480.

[119] A. Roberts, E. C. Duncan, P. Hargrave, et al., “Complications of Cardiopulmonary Bypass From an Anesthesia Perspective: A Clinical Review,” HCA Healthcare Journal of Medicine, 4, no. 1 (2023): 13-21.

[120] J. W. Frederiksen, “Cardiopulmonary Bypass in Humans: Bypassing Unfractionated Heparin,” The Annals of Thoracic Surgery 70 (2000): 1434-1443.

[121] S. E. Kimmel, M. Sekeres, J. A. Berlin, and N. Ellison, “Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary Bypass,” Anesthesia & Analgesia 94, no. 6 (2002): 1402-1408.

[122] H. A. Seifert, D. R. Jobes, T. Ten Have, et al., “Adverse Events After Protamine Administration Following Cardiopulmonary Bypass in Infants and Children,” Anesthesia & Analgesia 97, no. 2 (2003): 383-389.

[123] S. Brister, F. Ofosu, and M. Buchanan, “Thrombin Generation During Cardiac Surgery: Is heparin the Ideal Anticoagulant?,” Thrombosis and Haemostasis 70, no. 08 (1993): 259-262.

[124] T. F. Slaughter, T. H. LeBleu, J. M. Douglas, J. B. Leslie, J. K. Parker, and C. S. Greenberg, “Characterization of Prothrombin Activation During Cardiac Surgery by Hemostatic Molecular Markers,” Anesthesiology 80, no. 3 (1994): 520-526.

[125] L. H. Edmunds, “Inflammatory Response to Cardiopulmonary Bypass,” The Annals of Thoracic Surgery 66, no. 5 (1998): S12-S16.

[126] M. Kappers-Klunne, D. Boon, W. Hop, et al., “Heparin-induced Thrombocytopenia and Thrombosis: A Prospective Analysis of the Incidence in Patients With Heart and Cerebrovascular Diseases,” British Journal of Haematology 96, no. 3 (1997): 442-446.

[127] D. Musumeci and D. Montesarchio, “G-Quadruplex-Based Aptamers in Therapeutic applications,” Handbook of Chemical Biology of Nucleic Acids. (Springer, 2023): 2421-2446.

[128] Q. Yin, X. Zhang, S. Liao, X. Huang, C. C. Wan, and Y. Wang, “Potential Anticoagulant of Traditional chinese Medicine and Novel Targets for Anticoagulant Drugs,” Phytomedicine 116 (2023): 154880.

[129] S. M. Nimjee, J. Keys, G. Pitoc, G. Quick, C. Rusconi, and B. A. Sullenger, “A Novel Antidote-Controlled Anticoagulant Reduces Thrombin Generation and Inflammation and Improves Cardiac Function in Cardiopulmonary Bypass Surgery,” Molecular Therapy 14, no. 3 (2006): 408-415.

[130] C. K. Dyke, S. R. Steinhubl, N. S. Kleiman, et al., “First-in-human Experience of an Antidote-controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-antidote Pair for the Controlled Regulation of Factor IXa Activity,” Circulation 114, no. 23 (2006): 2490-2497.

[131] G. Lowe, A. Rumley, M. Woodward, et al., “Epidemiology of Coagulation Factors, Inhibitors and Activation Markers: The Third Glasgow MONICA Survey I. Illustrative Reference Ranges by Age, Sex and Hormone Use,” British Journal of Haematology 97, no. 4 (1997): 775-784.

[132] G. D. Lowe, A. Rumley, M. Woodward, E. Reid, and J. Rumley, “Activated Protein C Resistance and the FV: R506Q Mutation in a Random Population Sample,” Thrombosis and Haemostasis 81, no. 06 (1999): 918-914.

[133] M. Nagano, K. Kubota, A. Sakata, et al., “A Neutralizable Dimeric Anti-thrombin Aptamer With Potent Anticoagulant Activity in Mice,” Molecular Therapy-Nucleic Acids 33 (2023): 762-772.

[134] A. Krissanaprasit, E. Mihalko, K. Meinhold, et al., “A Functional RNA-origami as Direct Thrombin Inhibitor With Fast-acting and Specific Single-molecule Reversal Agents in Vivo Model,” Molecular Therapy (2024).

[135] B. P. Gray, M. D. Requena, M. D. Nichols, and B. A. Sullenger, “Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native state,” Cell Chemical Biology 27, no. 2 (2020): 232-244. e237.

[136] S. Liu and R. Kurzrock, “Toxicity of Targeted Therapy: Implications for Response and Impact of Genetic Polymorphisms,” Cancer Treatment Reviews 40, no. 7 (2014): 883-891.

[137] S. Baah, M. Laws, and K. M. Rahman, “Antibody-drug Conjugates—a Tutorial Review,” Molecules (Basel, Switzerland) 26, no. 10 (2021): 2943.

[138] O. K. Gaikwad, V. Y. Joshi, N. Singh, P. Das, and P. Datta, “Apoptosis-Based Therapeutics and Inhibitors in Clinical Trials or the Preclinical State,” Apoptosis and Human Health: Understanding Mechanistic and Therapeutic Potential. (Springer, 2024): 415-439.

[139] T. D. Nguyen, B. M. Bordeau, and J. P. Balthasar, “Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability,” Cancers 15, no. 3 (2023): 713.

[140] S. Shruthi and K. Bhasker Shenoy, “Cisplatin Resistance in Cancer Therapy: Causes and Overcoming Strategies,” ChemistrySelect 9, no. 25 (2024): e202401449.

[141] Z. Cao, R. Tong, A. Mishra, et al., “Reversible Cell-specific Drug Delivery With Aptamer-functionalized Liposomes,” Angewandte Chemie International Edition 48, no. 35 (2009): 6494-6498.

[142] B. Powell Gray, L. Kelly, D. P. Ahrens, et al., “Tunable Cytotoxic Aptamer-drug Conjugates for the Treatment of Prostate Cancer,” Proceedings of the National Academy of Sciences 115, no. 18 (2018): 4761-4766.

[143] J. M. Kwan, A. M. Fialho, M. Kundu, et al., “Bacterial Proteins as Potential Drugs in the Treatment of Leukemia,” Leukemia Research 33, no. 10 (2009): 1392-1399.

[144] S. Xie, Y. Sun, X. Zhao, et al., “An Update of the Molecular Mechanisms Underlying Anthracycline Induced Cardiotoxicity,” Frontiers in Pharmacology 15 (2024): 1406247.

[145] J. A. Gándara-Mireles, I. Lares-Asseff, E. A. Reyes Espinoza, et al., “Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children With Acute Lymphoblastic Leukemia: Nutritional Status as a Risk Factor for Cardiotoxicity in Children With Leukemia,” Nutrition and Cancer 76, no. 10 (2024): 952-962.

[146] K. Elumalai, S. Srinivasan, and A. Shanmugam, “Review of the Efficacy of Nanoparticle-based Drug Delivery Systems for Cancer Treatment,” Biomedical Technology 5 (2024): 109-122.

[147] S. M. Taghdisi, P. Lavaee, M. Ramezani, and K. Abnous, “Reversible Targeting and Controlled Release Delivery of Daunorubicin to Cancer Cells by aptamer-wrapped Carbon Nanotubes,” European Journal of Pharmaceutics and Biopharmaceutics 77, no. 2 (2011): 200-206.

[148] S. M. Taghdisi, N. M. Danesh, P. Lavaee, et al., “Double Targeting, Controlled Release and Reversible Delivery of Daunorubicin to Cancer Cells by Polyvalent Aptamers-modified Gold Nanoparticles,” Materials Science and Engineering: C (2016): 753-761.

[149] L. Zhang, M. Wang, Z. Zhu, et al., “A Novel pH-sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-mediated Strategy for Guiding Neuroblastoma Antitumor Therapy,” International Journal of Nanomedicine 16 (2021): 3217-3240.

[150] B. P. Gray, L. Kelly, K.-A. Steen-Burrell, et al., “Rapid Molecular Imaging of Active Thrombi in Vivo Using aptamer-antidote Probes,” Molecular Therapy-Nucleic Acids 31 (2023): 440-451.

[151] M. Ozturk, M. Nilsen-Hamilton, and M. Ilgu, “Aptamer Applications in Neuroscience,” Pharmaceuticals 14, no. 12 (2021): 1260.

[152] A. Setia, A. K. Mehata, V. Priya, et al., “Nanoparticles for Thrombus Diagnosis and Therapy: Emerging Trends in Thrombus-theranostics,” Nanotheranostics 8, no. 2 (2024): 127.

[153] D. Li, Y. Shi, and G. Liu, “Aptamer-Based Probes for Molecular Imaging,” Aptamers for Medical Applications: From Diagnosis to Therapeutics (2021): 31-52.

[154] M. M. Aljohani, D. Cialla-May, J. Popp, R. Chinnappan, K. Al-Kattan, and M. Zourob, “Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases,” Molecules (Basel, Switzerland) 27, no. 2 (2022): 383.

[155] A. Lichota, E. M. Szewczyk, and K. Gwozdzinski, “Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds,” International Journal of Molecular Sciences 21, no. 21 (2020): 7975.

[156] P. C. Blainey and S. R. Quake, “Dissecting Genomic Diversity, One Cell at a Time,” Nature Methods 11, no. 1 (2014): 19-21.

[157] D. Pensold and G. Zimmer-Bensch, “Methods for Single-cell Isolation and Preparation,” Single-cell Sequencing and Methylation: Methods and Clinical Applications 255 (2020): 7-27.

[158] S. Ishii, K. Tago, and K. Senoo, “Single-cell Analysis and Isolation for Microbiology and Biotechnology: Methods and Applications,” Applied Microbiology and Biotechnology 86 (2010): 1281-1292.

[159] H. Abe, J. Wang, K. Furukawa, et al., “A Reduction-triggered Fluorescence Probe for Sensing Nucleic Acids,” Bioconjugate Chemistry 19, no. 6 (2008): 1219-1226.

[160] L. Kelly, K. E. Maier, A. Yan, and M. Levy, “A Comparative Analysis of Cell Surface Targeting Aptamers,” Nature Communications 12, no. 1 (2021): 6275.

[161] M. D. Requena, B. P. Gray, and B. A. Sullenger, “Protocol for Purification of Cells in Their Native state Using Reversible Aptamer-antidote Pairs,” STAR Protocols 4, no. 3 (2023): 102348.

[162] Q. Jiang, Y. Shang, Y. Xie, and B. Ding, “DNA Origami: From Molecular Folding Art to Drug Delivery Technology,” Advanced Materials 36, no. 22 (2024): 2301035.

[163] C. P. Rusconi, E. Scardino, J. Layzer, et al., “RNA Aptamers as Reversible Antagonists of Coagulation Factor IXa,” Nature 419, no. 6902 (2002): 90-94.

[164] S. M. Nimjee, D. Dornbos, G. A. Pitoc, et al., “Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels,” Molecular Therapy 27, no. 7 (2019): 1228-1241.

[165] D. Lin, L. Shen, M. Luo, et al., “Circulating Tumor Cells: Biology and Clinical Significance,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 404.

[166] S. Rajput, P. K. Sharma, and R. Malviya, “Fluid Mechanics in Circulating Tumour Cells: Role in Metastasis and Treatment Strategies,” Medicine in Drug Discovery 18 (2023): 100158.

[167] C. Alix-Panabières and K. Pantel, “Challenges in Circulating Tumour Cell Research,” Nature Reviews Cancer 14, no. 9 (2014): 623-631.

[168] B. J. Green, T. Saberi Safaei, A. Mepham, M. Labib, R. M. Mohamadi, and S. O. Kelley, “Beyond the Capture of Circulating Tumor Cells: Next-generation Devices and Materials,” Angewandte Chemie International Edition 55, no. 4 (2016): 1252-1265.

[169] A. S. Drozdov, P. I. Nikitin, and J. M. Rozenberg, “Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association Between Accumulation in Tumors and Spleen,” International Journal of Molecular Sciences 22, no. 23 (2021): 13011.

[170] M. Labib, B. Green, R. M. Mohamadi, et al., “Aptamer and Antisense-mediated Two-dimensional Isolation of Specific Cancer Cell Subpopulations,” Journal of the American Chemical Society, 138, no. 8 (2016): 2476-2479.

[171] M. D. Requena, A. Yan, T. Llanga, and B. A. Sullenger, “Reversible Aptamer Staining, Sorting, and Cleaning of Cells (Clean FACS) With Antidote Oligonucleotide or Nuclease Yields Fully Responsive Cells,” Nucleic Acid Therapeutics 34, no. 1 (2024): 12-17.

[172] S. Mukherjee, P. Malik, and T. K. Mukherjee, “Isolation and Purification of Various Mammalian Cells: Single Cell Isolation,” Practical Approach to Mammalian Cell and Organ Culture. (Springer, 2023): 261-317.

[173] N. Rabiee, S. Chen, S. Ahmadi, and R. N. Veedu, “Aptamer-engineered (nano) Materials for Theranostic Applications,” Theranostics 13, no. 15 (2023): 5183.

[174] X. Zheng, Z. Huang, Q. Zhang, G. Li, M. Song, and R. Peng, “Aptamer-functionalized Nucleic Acid Nanotechnology for Biosensing, Bioimaging and Cancer Therapy,” Nanoscale (2025).

[175] T. Hachigian, D. Lysne, E. Graugnard, and J. Lee, “Customizable Aptamer Transducer Network Designed for Feed-forward Coupling,” ACS Omega 6, no. 41 (2021): 26888-26896.

[176] J. Zhu, D. Wang, H. Yu, et al., “Advances in Colorimetric Aptasensors for Heavy Metal Ion Detection Utilizing Nanomaterials: A Comprehensive Review,” Analytical Methods 15, no. 46 (2023): 6320-6343.

[177] H. Sun, D. Zhao, Y. He, H. M. Meng, and Z. Li, “Aptamer-Based DNA Allosteric Switch for Regulation of Protein Activity,” Advanced Science 11, no. 30 (2024): 2402531.

[178] Z. W. Wong and S. Y. New, “Recent Advances in Biosensors Based on Hybridization Chain Reaction and Silver Nanoclusters,” Small Methods (2025): 2401436.

[179] N. Kacherovsky, I. I. Cardle, E. L. Cheng, et al., “Traceless Aptamer-mediated Isolation of CD8+ T Cells for Chimeric Antigen Receptor T-cell Therapy,” Nature Biomedical Engineering 3, no. 10 (2019): 783-795.

[180] Y. Wang, Y. Liu, L. L. Wang, Q. L. Zhang, and L. Xu, “Integrating Ligands Into Nucleic Acid Systems,” Chembiochem 24, no. 18 (2023): e202300292.

[181] Q. Hu, J. Yan, and K. Ren, “DNA Self-Assembly: A Tool to Improve Biochemical Reaction Performance,” ACS Materials Letters 6, no. 9 (2024): 4183-4208.

[182] D. M. El Shehaby, M. K. Mohammed, N. E. Ebrahem, M. M. Abd El-Azim, I. G. Sayed, and S. A. Eweda, “The Emerging Therapeutic Role of some Pharmacological Antidotes in Management of COVID-19,” The Egyptian Journal of Bronchology 16, no. 1 (2022): 5.

[183] J. Lloyd, C. H. Tran, K. Wadhwani, C. Cuba Samaniego, H. K. Subramanian, and E. Franco, “Dynamic Control of Aptamer-ligand Activity Using Strand Displacement Reactions,” ACS Synthetic Biology 7, no. 1 (2018): 30-37.

[184] D. Kobylarz, M. Noga, A. Frydrych, et al., “Antidotes in Clinical Toxicology—Critical Review,” Toxics 11, no. 9 (2023): 723.

[185] D. Kobylarz, M. Noga, A. Frydrych, et al., “Antidotes in Clinical Toxicology—Critical Review,” Toxics 11 (2023): 723.

[186] X. Wu, J. Chen, M. Wu, and J. X. Zhao, “Aptamers: Active Targeting Ligands for Cancer Diagnosis and Therapy,” Theranostics 5, no. 4 (2015): 322.

[187] C. P. Rusconi, J. D. Roberts, G. A. Pitoc, et al., “Antidote-mediated Control of an Anticoagulant Aptamer in Vivo,” Nature Biotechnology 22, no. 11 (2004): 1423-1428.

[188] K. Bompiani, D. Monroe, F. Church, and B. Sullenger, “A High Affinity, Antidote-controllable Prothrombin and Thrombin-binding RNA Aptamer Inhibits Thrombin Generation and Thrombin Activity,” Journal of Thrombosis and Haemostasis 10, no. 5 (2012): 870-880.

[189] S. Oney, R. T. Lam, K. M. Bompiani, et al., “Development of Universal Antidotes to Control Aptamer Activity,” Nature Medicine 15, no. 10 (2009): 1224-1228.

[190] M. E. Kleinman, K. Yamada, A. Takeda, et al., “Sequence-and Target-independent Angiogenesis Suppression by siRNA via TLR3,” Nature 452, no. 7187 (2008): 591-597.

[191] M. Schröder and A. G. Bowie, “TLR3 in Antiviral Immunity: Key Player or Bystander?,” Trends in Immunology 26, no. 9 (2005): 462-468.

[192] K. M. Bompiani, R. S. Woodruff, R. C. Becker, S. M. Nimjee, and B. A. Sullenger, “Antidote Control of aptamer Therapeutics: The Road to a Safer Class of Drug Agents,” Current Pharmaceutical Biotechnology 13, no. 10 (2012): 1924-1934.

[193] H. Li, Q. Luo, H. Zhang, et al., “Nanomedicine Embraces Cancer Radio-immunotherapy: Mechanism, Design, Recent Advances, and Clinical Translation,” Chemical Society Reviews 52, no. 1 (2023): 47-96.

[194] J. T. Davis, “G-quartets 40 Years Later: From 5′-GMP to Molecular Biology and Supramolecular Chemistry,” Angewandte Chemie International Edition 43, no. 6 (2004): 668-698.

[195] J. Carr and N. Silverman, “The Heparin-protamine Interaction: A Review,” Journal of Cardiovascular Surgery 40, no. 5 (1999): 659.

[196] M. Yavari and R. C. Becker, “Anticoagulant Therapy During Cardiopulmonary Bypass,” Journal of Thrombosis and Thrombolysis 26 (2008): 218-228.

[197] B. A. Danek, K. E. Kearney, C. J. Chung, et al., “The Contemporary Role of Protamine in the Cardiac Catheterization Laboratory,” Catheterization and Cardiovascular Interventions 102, no. 1 (2023): 111-120.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.